ascopubs.org

PD-1 inhibitors versus PD-L1 inhibitors in PD-L1–negative advanced non-small cell lung cancer: A meta-analysis of survival outcomes.

Predictive value of the triglyceride-glucose index for the efficacy of immunotherapy in patients with advanced NSCLC: A retrospective study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Forbes

A New Immunotherapy For Cancer: PD-L2

PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...
The American Journal of Managed Care

Will Subcutaneous PD-1/PD-L1 Inhibitors Be a Game Changer?

With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...
ascopubs.org

PD-1/PD-L1 inhibitors as neoadjuvant therapies in resectable non-small cell lung cancer, including their effects in various PD-1 expression subtypes: A meta-analysis.

Perioperative immunotherapy for stage II-III NSCLC patients: A retrospective real-world analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a ...